Arovella Therapeutics (ALA) Q2 2026 TU earnings summary

Executive summary

• Filed IND application for ALA-101 with the U.S. FDA, advancing toward first-in-human Phase 1 trial for CD19-positive lymphoma and leukemia.

• Selected SAPRO as CRO for the Phase 1 trial, with trial start-up activities underway and expected commencement in early 2026.

• Demonstrated potent in vitro activity of CLDN18.2-targeting CAR for ALA-105 program, supporting expansion into solid tumors.

• Exercised option to in-license additional CAR targets and iNKT-related technology from Baylor College of Medicine.

• Appointed Dr Andrew Nash as Non-Executive Director, with intention to transition to Non-Executive Chairman.

Financial highlights

• Cash and cash equivalents at 31 December 2025 totaled $19.4 million.

• Quarterly cash outflows from operating activities were $2.5 million, with R&D and staff costs comprising 90% of outflows.

• Payments to related parties for the quarter were $154,063, covering director fees and executive salaries.

• Estimated 7.6 quarters of funding available based on current cash burn.

Outlook and guidance

• Phase 1 clinical trial for ALA-101 expected to commence early 2026, with funding secured to complete enrollment and report initial safety and efficacy data.

• Continued progress anticipated in solid tumor program targeting CLDN18.2 and integration of IL-12-TM armouring technology.

• Ongoing review of new technologies for potential acquisition to enhance or expand the CAR-iNKT cell platform.